The latent membrane protein (LMP1) encoded by Epstein-Barr virus (EBV) has been suggested to be one of the major oncogenic factors in EBV-mediated carcinogenesis. RNA-cleaving DNA enzymes are catalytic nucleic acids that bind and cleave a target RNA in a highly sequence-specific manner. In this study, we explore the potential of using DNAzymes as a therapeutic approach to EBVassociated carcinomas by targeting the LMP1 gene. In all, 13 different phosphorothioate-modified ''10-23'' deoxyribozymes (DNAzymes) were designed and synthesized against the LMP1 mRNA and transfected into B95-8 cells, which constitutively express the LMP1. Fluorescence microscopy was used to examine the cellular uptake and distribution in B95-8 cells. As demonstrated in Western blots, three out of 13 deoxyribozymes significantly downregulated the expression of LMP1 in B95-8 cells. These DNAzymes were shown to markedly inhibit B95-8 cell growth compared with a disabled DNAzyme and untreated controls, as determined by an alamarBlue Assay. It was further demonstrated that these DNAzymes arrested the B95-8 cells in G0/G1 using flow cytometry. Interestingly, the active DNAzymes could also downregulate the expression of Bcl-2 gene in treated cells, suggesting a close association between the LMP1 and Bcl-2 genes and their involvement in apoptosis. This was further confirmed with the result that the DNAzymes could induce the release of cytochrome c from mitochondria, which is the hallmark of the apoptosis. The present results suggest that the LMP1 may present a potential target for DNAzymes towards the EBV-associated carcinoma through cell proliferation and apoptosis pathways.
E pstein-Barr virus (EBV) is a gamma herpesvirus infecting more than 90% of adults worldwide and is the first human virus identified to be associated with human cancers. 1 EBV has been implicated in the pathogenesis of several human malignancies including lymphoproliferative malignancies such as Burkitt's and Hodgkin's lymphomas as well as epithelial tumors, including nasopharyngeal carcinoma (NPC) and gastric carcinoma. 2 More recently, there have been scattered reports linking EBV with typical epithelial cancers of other primary sites including breast, lung, colon and prostate carcinomas. 3 These studies suggested that EBV, rather than being associated with restricted groups of uncommon malignancies, might in fact play an oncogenic role in a variety of human epithelial cancers and possibly also in hyperplasias and certain dysplasias preceding carcinomas.
Latent membrane protein 1 (LMP1) is considered as a major oncogenic protein encoded by EBV because it could transform rodent fibroblasts and was tumorigenic in the nude mice. 4 LMP1 is an integral membrane protein composed of a short cytoplasmic N-terminus of 24 amino acids, six transmembrane domains of 162 amino acids and a cytoplasmic C-terminus of 200 amino acids. The six hydrophobic transmembrane domains facilitate spontaneous self-oligomerization and create a complex that constitutively activates cell-signaling pathways via a cytoplasmic C-terminus that mimics tumor necrosis factor (TNF) receptor superfamily members. While the C-terminal activating region 1 (CTAR1) of LMP1 is located proximal to the membrane and binds to the TNF receptor-associated factors (TRAFs), the CTAR2 is located toward the far C-terminus of LMP1 and binds the TNF receptor-associated death domain protein (TRADD) and receptor-interacting protein (RIP). Consequently, LMP1 can trigger several signaling pathways that lead to the activation of several transcription factors, including NF-kB, STATs and AP-1.
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Activation of NF-kB or AP-1 by LMP1 has been linked to the upregulation of some cellular proteins and inhibition of apoptosis. Depending on the cell types, expression of LMP1 has been shown to play different roles in response to biological and physiological stimulus. For example, the LMP1 expression was essential in the immortalization of the EBV-infected B cells, and in human epithelial cells LMP1 was suggested to be involved in tumor progression and invasions. More significantly, LMP1 is expressed in the majority of EBV-associated human malignancies, which supports the notion that the LMP1 may be one of the key factors contributing to EBV-mediated tumorigenesis. 8 Therefore, genetic manipulation of the LMP1 expression may provide a novel strategy for the treatment of EBV-associated human cancers.
Currently, there are several commonly used technologies for gene suppression, which include antisense oligonucleotides, ribozymes, DNAzymes and RNA interference (RNAi). The relative merits of antisense, RNAi, ribozymes and DNAzymes for sequence-specific knockdown of target RNA in different situations were recently compared by Scherer and Rossi. 9 DNAzymes are synthetic, singlestranded DNA catalysts that can be engineered to bind to their complementary sequence in a target messenger RNA (mRNA) through Watson-Crick base pairing. 10 A general model for the DNAzyme has been proposed, and is known as the ''10-23'' model. DNAzymes following the ''10-23'' model, also referred to simply as ''10-23 DNAzymes'', have a catalytic domain of 15 deoxyribonucleotides, flanked by two substrate-recognition domains of seven to nine deoxyribonucleotides each. In vitro analyses show that this type of DNAzyme can effectively cleave its substrate RNA at purine:pyrimidine junctions under physiological conditions. 11 These agents have been used in a number of in vitro and in vivo applications to inhibit the expression of their target gene 12 and their dependent genes. 13 Their capacity to block development of a diverse range of pathologies in animal models suggests a potential use of DNAzymes as therapeutic tools. [12] [13] [14] [15] [16] [17] In this report, we designed and constructed the specific DNAzymes that were shown to be effective in suppressing expression of the target protein LMP1 and affecting some LMP1-associated biological pathways. These results demonstrated the feasibility of targeting the LMP1 mRNA as a potential therapeutic strategy for EBVassociated carcinomas.
Materials and methods

Cell culture
The B95-8 cell line (ATCC CRL-1612) was grown in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS, GIBCO). All media were supplemented with 10 mg/ml streptomycin and 10 IU/ml penicillin and all cultures were incubated in a humidified atmosphere of 5% CO 2 at 371C.
Design and construction of DNAzymes
EBV has been shown to possess some mutations in LMP1 and these sequence changes may be associated with the viral oncogenic potential. In order to identify some conserved regions in the LMP1 gene for DNAzyme targeting, we aligned the LMP1 sequences from B95-8 cells with a panel of eight EBV isolates, including representatives of four defined groups of European LMP1 variants (groups A-D) and Chinese NPC-derived LMP1. 18 All DNAzymes contained the 10-23 catalytic motif (ggctagctacaacga) and 9 bp hybridizing arms specific for RU cleavage sites (R ¼ G or A) in the conserved regions of the LMP1 transcript. DNAzymes were selected in the study if their hybridization stability with their targets (D G1) is oÀ25 kcal/mol. 19 Based on the analyses of sequences, thermodynamics and site distribution within the LMP1 gene, 13 DNAzymes were synthesized with two phosphorothioate linkages on both arms ( Table 1 ). The control oligonucleotide of DZ10 was designed by inverting catalytic core sequence. Where indicated, DZ10 DNAzyme was labeled with a fluorescein isothiocyanate (FITC) at the 5 0 -end for cellular uptake study.
DNAzyme transfection of B95-8 cells
Cells were split the day before transfection. On the day of transfection, cells were harvested and washed once with cold PBS. 2 Â 10 6 cells per well were seeded in a six-well plate in 1 ml of fresh RPMI 1640 medium containing 10% FBS. The DNAzymes/tetra(4-methylpyridyl) porphyrine (TMP) mixtures were made at a charge ratio of 1 with 2 mM DNAzyme oligonucleotides as described. 20 The mixture was then added to the cells and incubated at 371C for 4 hours, followed by the addition of complete medium to the wells and further incubation for 20 hours.
Fluorescence microscopic analysis
At 20 hours after transfection, cells were rinsed twice with PBS, once with 2 ml of .2 M glycine (pH 2.8) buffer, and then once with PBS. Cell nuclei were stained with 5 ng/ml Hoescht 33258 or 50 ng/ml PI in PBS for 5 minutes prior to fixing with 4% paraformaldehyde in PBS for 30 minutes at ambient temperature. 21 Cells were rinsed with PBS and then mounted in 75% glycerol. Microphotographs were acquired under UV (for Hoescht staining) and B2 (for FITC-labeled DNAzymes) filters using a Nikon Optiphot-2 microscope (Tokyo, Japan) equipped with a Nikon Microflex UFX-DX photomicrographic attachment.
Western blot analysis
B95-8 cells grown in six-well plates were transfected as described above and incubated for 20 hours at 371C in medium supplemented with 10% FBS. Cells were then washed with ice-cold PBS and lysed in the lysis buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 2% SDS, 5 mM DTT, 10 mM PMSF, Proteinase inhibitors mix) for 30 minutes on ice. The lysate was centrifuged for 5 minutes at 14,000 rpm in a microfuge. After protein quantification by the BCA Assay Reagent (Pierce Chemical, Inc.), 50 mg of the total proteins from the DNAzyme-, control ODNor mock-transfected cells were mixed with sample buffer and boiled for 5 minutes. The samples were then resolved on 10% polyacrylamide SDS gel and transferred onto a nitrocellulose membrane by electroblotting. The membrane was incubated in blocking buffer (TBS containing 5% skim milk and .1% Tween 20) for 2 hours, followed by incubation with primary antibody diluted in the same buffer (1:1000). The membrane was washed in TBS containing .1% Tween 20 and further incubated with a secondary antibody that could be detected using a peroxidase-conjugated anti-IgG at 1:10,000. Protein expressions were determined using a supersignal chemiluminescence system (ECL, Pierce), followed by exposure to autoradiographic film. The study employed antibodies against LMP1 (cs1-4, DAKO), a-tubulin (sc-5286, Santa Cruz Biotechnology Inc.), Bcl-2 (C-2, sc-7382, Santa Cruz Biotechnology Inc.) and CytoC (K257-100, BioVision), Ik-Ba (sc-203, Santa Cruz Biotechnology Inc.) and NFkB p65 (sc-109, Santa Cruz Biotechnology Inc.).
Cell proliferation assays
B95-8 cells grown in 96-well micro-titer plates were transfected at .5, 1 and 2 mM of DNAzymes or control ODN as described above. Cells were then incubated at 371C and 25 ml of alamarBlue Assay reagent (Serotec Ltd) was added to each well at different time points. The plates were allowed for a further incubation of 3 hours and analyzed spectrophotometrically (absorbance at 570 and 600 nm, Bio-Tek Inc.).
Cell cycle analysis
The transfected B95-8 cells were incubated for different times at 371C in medium supplemented with 10% FBS. Untreated and treated cells were then washed with ice-cold PBS and suspended in 75% ethanol at À201C overnight. Fixed cells were centrifuged and washed with PBS twice. For cell cycle analysis, cells were stained with 50 mg/ml of PI and .1% of RNase A in 400 ml PBS in a light-proof tube at 251C for 30 minutes. Stained cells were assayed on FACSort (Becton Dickinson) and the cell cycle parameters were determined using the CellQuest software program (Becton Dickinson).
Cytochrome c release assay
The cells were transfected as described above. The proteins from cytosolic fraction and mitochondrial fraction were extracted using cytochrome c apoptosis assay kit (BioVision), according to the manufacturer's instruction. Western blots were performed using a CytoCspecific antibody (K257-100, BioVision).
Results and discussion
Cellular uptake and distribution of LMP1 DNAzymes
A cell line B95-8 was used to examine DNAzyme efficacy in downregulation of the LMP1 gene expression and impact on cellular functions. To facilitate delivery of DNAzyme oligonucleotides into cells, a cationic porphyrin, TMP, was used as a transfection reagent for intracellular delivery. 20 In order to increase DNAzyme stability in cells, two phosphorothioate linkages were incorporated into each of the arms in DNAzymes, which has been shown to be an efficient way to protect DNAzyme oligonucleotides from enzymatic degradation. 22 When the transfected cells were subjected to fluorescent microscopic analysis, efficient delivery was observed using the TMP-complexed phosphorothioate-Dz. Importantly, a significant nuclear delivery was seen at 24-hour time point (Fig 1) . As for all the oligonucleotide-based agents such as antisense, ribozyme or siRNA, the DNAzyme delivery has been the major hurdle in assay of its efficacy. Many types of delivery agents have been widely used for this purpose, including liposomes, nanoparticles or electroporation. 23 In this study, TMP was shown to be a simple and efficient transfection reagent due to its high complexing efficiency, low cellular toxicity and preferential nuclear uptake.
Inhibition of LMP1 protein expression in B95-8 cells using DNAzymes
DNAzymes are enzymatic molecules composed entirely of DNA that can be made to bind and cleave any RNA molecule both in vitro and in vivo. However, like other agents that function by hybridization with singlestranded RNA, the DNAzyme must compete with the target's own stable intramolecular base pairing, which forms its characteristic secondary structures. Fortunately, the 10-23 DNAzyme cleavage sites are plentiful in most biological substrates and thus provide a host of opportunities to achieve maximum cleavage efficiency. In addition to target site accessibility, the thermodynamics of enzyme-substrate interactions also have a strong influence on the efficiency of DNAzymemediated hydrolysis of a long RNA. 24 Taking into consideration these factors, we designed 13 different 10-23 DNAzymes targeted against AU or GU sites along the full-length LMP1 mRNA (Table 1) . These DNAzymes were transfected into B95-8 cells and assayed for their effect on the LMP1 expression at the protein level using Western blotting. As shown in Figure 2 , DNAzymes DZ1, DZ7 and DZ10 (2 mM) strongly inhibited LMP1 protein expression in B95-8 cells, compared with a control ODN, TMP transfection reagent and untreated controls. Based on the initial screening results, one of the efficient DNAzymes, DZ10, was used for further study and confirmed that DZ10 could inhibit LMP1 expression in B95-8 cells in a dose-dependent manner (Fig 3) .
Impact of LMP1 DNAzymes on B95-8 cell growth
There have been many reports showing that the EBV LMP1 is one of several latently expressed genes essential for the transformation of B lymphocytes and affects cellular growth and differentiation of epithelial cells in vitro. 25, 26 The broad expression of LMP1 in undifferentiated NPC suggests this viral oncoprotein as a key effector molecule in NPC pathogenesis. 8 We previously showed that the EBV LMP1 might modulate EGFR promoter activity in a NF-kB-dependent manner in NPC. 27 Thus, downregulation of the LMP1 expression could result in a growth inhibition in LMP1-expressing cells.
To examine the effect of downregulation of LMP1 on cell growth, active DNAzymes DZ1, DZ7 and DZ10 were transfected into B95-8 cells and the proliferation rate was assessed by alamarBlue assay. As shown in Table 2 , the proliferation rate was inhibited in all the Dz-treated cells at 24-hour time point, followed by a recovery at 48-and DNAzyme-mediated suppression of LMP1 expression Z-X Lu et al 72-hour points, which may suggest a gradual degradation of the transfected oligonucleotides within the transfected cells. When three DNAzymes were combined and transfected into the cells, an increase in the inhibitory effect was observed, compared with any of individual DNAzyme treatment. This combined effect may be due to the multiple targeting of the accessible site within the LMP1 mRNA structures.
To further investigate the cause of the reduced cell proliferation rate in the DZ-treated B95-8 cells, flow cytometry was employed to study the effect of the DNAzymes on cell cycle. The results showed that DZ-7-treated cells were arrested in G0/G1 at 24 hours post transfection, with a significant reduction of cells in G2/M phase and a marginal reduction of cells in S phase (Table 3 ). This result correlated well to the data from the cell proliferation assay at 24 hours time point (Table 2) , further suggesting an involvement of the LMP1 gene in cell proliferation in NPC development.
Inhibition of Bcl-2 protein expression and induced apoptosis in B95-8 cells with LMP1 DNAzymes
There have been reports that the tumorigenicity of the EBV-positive cells was associated with an increase in the antiapoptotic protein Bcl-2 and resistance to apoptosis. 28 Abdulkarim et al. 29 reported that antiviral agent Cidofovir could downregulate the EBV oncoprotein LMP1 expression, which was associated with a decrease in antiapoptotic Bcl-2 protein and an increase of the proapoptotic Bax protein in Raji (BL) and C15 (NPC) cells. However, the mechanism of Codofovir's effect on the LMP1 and bcl-2 protein expression was not defined. Here, we used the LMP1-specific DNAzymes to further investigate the association of the viral LMP1 and cellular Bcl-2 protein in B95-8 cells. Western blotting results indicated that the active LMP1 DNAzymes could concomitantly downregulate the expression of Bcl-2 gene in the treated cells (Fig 4a and b) . Analyses of the proteins of cytosolic fraction and mitochondrial fraction, respectively, using cytochrome c apoptosis assay kit (BioVision) confirmed that the active DNAzymes could also induce the release of cytochrome c from mitochondria, which is the hallmark of the apoptosis (Fig 5a and b) .
Taken together, these results, for the first time, demonstrated a direct relationship between the LMP1 and Bcl-2 at a gene-specific level and their involvement in apoptosis. Modulation of LMP1-induced cellular NF-kB signal pathway in CNE1-LMP1 cells by DNAzymes LMP1-mediated activation of NF-kB is one of the major signal transduction pathways involved in cell growth and apoptosis in the EBV-associated NPC. 30 In normal cells, NF-kB is sequestered by inhibitory molecules, IkBs. When LMP1 activates the NF-kB pathway, one of the inhibitory molecules, IkBa, is degraded by uniquitination, which leads to release and nuclear transportation of NF-kB. 31 To elucidate the mechanism whereby the LMP1-specific DNAzymes promote apoptotosis in LMP1-expressing cells, we examined if downregulation of LMP1 by DNAzymes could affect the NF-kB pathway. As shown in Figure 6 , the NF-kB level in DNAzyme-treated cells remained unchanged while the IkBa level was significantly increased compared with controls. This result suggests that suppression of LMP1 expression leads to accumulation of the IkBs in cells, which could have a global effect on cell functions regulated via the NF-kB pathway, including cell proliferation and apoptosis.
In conclusion, we have developed the active DNAzymes that could suppress the EBV LMP1 expression, inhibit the cell proliferation in the LMP-expressing B95-8 cells and increase apoptosis by downregulation of the bcl-2 expression. The biological activity of the DNAzymes was shown to be mediated via the NF-kB signaling pathway. The present results suggest that the LMP1 could be a potential molecular target for nucleic acid-based therapeutics, such as DNAzymes, towards the EBV-associated carcinomas through cell proliferation and apoptosis pathways. 
Figure 6
Effect of DNAzymes on NF-kB signal pathway. CNE1-LMP1 cells grown in six-well plates were transfected with DNAzymes (DZ1, DZ7 or DZ10 at 2 mM), or mock-transfected and incubated in medium containing 10% FBS at 371C for 24 hours. Total cell lysates were analyzed by Western blots (a). Expression level for each protein was estimated by densitometry and presented as a ratio to the loading control a-tubulin (b). Antibodies: IkB-a (C-15): sc-203, NF-kB p65 (a): sc-109, from Santa Cruz.
